UVA registers Phase 1b/2 trial of Verastem's avutometinib/defactinib in pancreatic cancerSep 17Trial updateavutometinibdefactinib
Verastem amends Oberland note agreement, adds new revenue-linked notes trancheAug 6Regulatory decisionVerastem, Inc.
Verastem starts dosing in all three VS-7375 registration trials, secures added $75M financingAug 6Quarterly updateVerastem, Inc.VS-7375
Verastem registers open-label extension study for avutometinib-defactinib in LGSOCAug 5Trial updateavutometinibdefactinib
ROCKIF trial of defactinib in ovarian cancer terminated for lost funding; results postedJul 31Trial updatedefactinibVerastem, Inc.
Sign inSign in